Multiple sclerosis (MS) is the commonest non-traumatic disabling disease to affect young adults. The incidence of MS is increasing worldwide, together with the socioeconomic impact of disease. The underlying cause of MS, and mechanisms behind this increase remain opaque, although complex gene-environment interactions almost certainly play a significant role. The epidemiology of MS indicates that low vitamin D, smoking, childhood obesity and infection with the Epstein-Barr virus are likely to play a role in disease development.
studies indicate that environment trumps genetics and argue strongly for prevention studies targeting known environmental risk factors.
Being truly EBV negative protects you from developing MS [12] [13] ; symptomatic EBV infection (i.e. infectious mononucleosis), doubles your chances of getting MS [14] . Evidence regarding the mechanism via which EBV increases MS risk is heterogenous; molecular mimicry is historically a popular theory [15] , more recently EBV-induced B-cell immortalisation and/or transformation is been thought to play an important role in disease development [16] .
MS is increasingly a global disease [2] . MS prevalence increases with latitude, however this gradient is decreasing in Norway and USA, the two countries where this has been studied [17] . The latitudinal gradient in MS prevalence is strongly correlated with UVB exposure, which stimulates cutaneous vitamin D (vD) production. Low vD levels, decreased intake of vD, reduced outdoor activity and increased MS susceptibility associated with genetic polymorphisms causing low vD levels have implicated vD in the causal pathway of MS [18] .
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MS is more common in females, but this has not always been the case. In case series from the early 1900s the sex ratio was almost equal. Since then, the sex ratio has been steadily been increasing, and is now close to 3:1 (F:M) in most developed countries [19] . Smoking, which increases MS risk by approximately 50%, can explain up to 40% of the increased incidence of MS in women [20] . Prior to the second world war few women smoked, but the number of women smoking rapidly increased post-war, mirroring the increasing incidence of MS in women [20] . The observation that organic solvents [21] and smoked tobacco [22] , but not oral tobacco or snoef [23] , are associated with MS has led to the hypothesis that these agents cause post-translational modifications via antigen presentation occurring in the lungs.
It is likely that MS risk modification occurs throughout life, starting in utero [10] . The monthof-birth effect and increased concordance in dizygotic twins compared to siblings, indicates that the intrauterine environment is important in establishing MS risk; it is unclear whether this is due to common environmental exposures, or epigenetic mechanisms, or both [10] .
There is a genetic influence on MS susceptibility; about one in eight patients have a family history of MS [24] . Concordance in female monozygotic twins approaches 30% in the UK and Canada, but is as low as ~8.5% in southern Europe [25] .
The main genetic risk associated with MS resides in HLA-DRB1*15 and/or other loci in strong linkage disequilibrium with this allele [26] . Heterozygotes for HLA-DRB1*15:01 have an OR of MS >3 and homozygotes >6 [26] , yet the mechanism remains unknown. It is hypothesised that HLA-DRB1*15:01's role is via antigen presentation, however this does not explain the protective effects of class 1 alleles (e.g. HLA-A*02:01) [27] .
Genome-wide association studies have identified more than 150 single nucleotide polymorphisms (SNPs) associated with MS susceptibility [28] . The OR associated with the majority of these is small, around 1.1-1.2. Many of these SNPs lie close to genes associated
with immune function, typically in regulatory rather than coding regions. Functional variants identified include those within IL7R[29], IL2RA [30] , TNFR1 [31] , BAFF [32] and CYP2R1 [33] . Mendelian randomisation studies have provided evidence for a role of vitamin D [33] [34] [35] and obesity [36] as independent risk factors causing disease.
Recent work has uncovered genetic differences between RRMS and PPMS [37] not previously detected in GWAS, most likely due to the under-representation of PPMS in these cohorts. Genetic variants associated with other progressive neurological disorders are relatively over-represented in progressive MS [37] . Similar genetic risk exists when all MSassociated alleles are taken in account, indicating additional risk for progressive disease superimposed on underlying genetic susceptibility. Evidence of differential gene transcription between RRMS and PPMS [38] , again hints at individual differences on a background of shared genetic risk.
Pathology & Immunology
In Charcot's original descriptions of the pathology associated with sclerose en plaques, he described "sclerosed plaques" affecting the periventricular area, pons, and spinal cord [39] .
The characteristic pathological hallmark of MS is perivenular inflammatory lesions, leading to demyelinating plaques [40] . The inflammatory infiltrates contain T-lymphocytes, dominated by MHC Class I restricted CD8+ T-cells; B-cells and plasma cells are also present, although in much lower numbers [41] . Oligodendrocyte damage and demyelination occur as a result of inflammation. Axons are relatively preserved in the early stages of the disease, however as disease progresses irreversible axonal damage develops [42] . The "classical active lesion", with profound lymphocytic inflammation, predominates in RRMS.
It is seen less commonly in progressive disease, where lesions tend to have an inactive lesion core surrounded by a narrow rim of activated microglia and macrophages [43] .
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Despite a clinical distinction between RRMS and progressive MS, pathologically-defined inflammatory changes are seen in both, albeit to a greater degree in relapsing-remitting disease. The composition of the inflammatory infiltrate in relapsing-remitting and progressive MS is similar, although the proportion of B-cells and plasma cells is higher in progressive MS [44] . Whether the cytokine profile or activation stage of T-cells and B-cells differs between clinical disease types remains unclear [41] .
Remyelination is seen in all disease stages, most commonly in progressive disease [41] .
Patients with SPMS have higher levels of demyelination, and a reduction in axonal density in the normal appearing white matter in the cervical spinal cord in PPMS [45] . There is no single characteristic histological difference between MS subtypes, instead a difference in the proportion of areas showing particular characteristics. Thus whilst three clinical forms of MS have been defined, the pathological changes form a continuum. This fits with gradual clinical disease evolution in patients, from relapsing-remitting to secondary progressive MS over a period of years.
Clinical features
MS is a journey from being at risk, through the asymptomatic, prodromal and symptomatic phases of the disease. MS is typically suspected when a person presents with a clinically isolated syndrome (CIS). This can be mono-or poly-symptomatic depending on the location of the eloquent lesion(s). The most commonly seen presentations are optic neuritis, brainstem and spinal cord syndromes, however numerous other less common presentations exist, including cortical presentations, such as dominant parietal lobe syndromes.
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MS relapses usually develop subacutely over hours to days, reach a plateau lasting several weeks, then gradually recover. Gross clinical recovery from relapses often appears complete in early MS, however most relapses leave behind some damage. For example, following acute optic neuritis gross visual acuity may recover, but colour vision, contrast sensitivity and depth perception abnormalities persist. As neuronal reserve is lost, recovery from relapses becomes incomplete, and neurological deficits accrue leading to sustained disability.
For every clinical attack approximately ten "asymptomatic" lesions are noted on MRI.
Symptomatology results from a combination of location and size -a small lesion in an eloquent area is likely to cause symptoms. Macroscopic, or MRI-visible, lesions are the tip of the iceberg; with many more lesions can be seen at microscopic level and even more in deep and cortical grey matter.
Secondary progressive MS typically develops 10-15 years after RRMS onset, with a gradual evolution from discrete relapses to slowly progressive disease. There is not a distinct transition between disease types, rather relapses occur on a background of subtle progression, prior to progression being dominant. The cognitive impairment and progressive MRI atrophy seen in early MS indicate that neurodegeneration is present from clinical onset.
In 5-15% of cases there is a primary progressive onset (primary progressive MS, PPMS), typically with gradual accrual of progressive disability involving one dominant neuronal system. The commonest presentation is with a progressive spastic paraparesis, but sensory ataxia, cerebellar ataxia, cognitive and progressive visual failure are well described PPMS variants.
There has been a reduction in the proportion of people with PPMS [46] . This is likely related to the fact that there are no licensed treatments for PPMS; patients may be labelled as having relapsing MS in order to receive treatment, raising ethical questions about the division of MS into distinct subtypes. This artificial division of MS into different diseases was driven by the pharmaceutical industry to get interferon-beta licensed under the orphan drug act in the US.
Paediatric MS is considerably rarer than adult onset disease, with a highest reported incidence of 2.9/100,000 [47] . The diagnosis is based on repeated episodes of demyelination separated by time and space. Differentiating paediatric MS from ADEM can be challenging, as paediatric MS may be multifocal at onset [47] . Relapse rates may be higher, but physical recovery tends to be more complete. Few treatments are licensed for use in children, and referral to a paediatric neurologist with expertise in demyelinating disorders is recommended where the diagnosis is suspected.
Given the above, MS can be thought of as a single disease existing within a spectrum extending from relapsing ("inflammatory dominant") to progressive ("neurodegeneration dominant"), in keeping with the 2013 revisions to the clinical course of MS [48] . At present, MS definitions place artificial distinctions between patients with progressive and patients with relapsing disease. Instead, these subtypes should be seen as points on a continuum of disease, which should be expanded to include prodromal (i.e. radiologically isolated) disease.
Preclinical disease and the at-risk population
MS has an at-risk period prior to preclinical and clinical phases [49] . Migration studies indicate that the time from exposure to environmental risk factors and the onset of disease is 10-20 years [49] . Pathological studies indicate that the preclinical phase of MS could be decades; a Danish series found that a quarter of cases with post-mortem pathological evidence of MS were never diagnosed with MS in life [50] .
Accepted Article
MS begins before the first clinical attack; most patients presenting with a CIS have older, inactive, lesions on their MRI. Radiologically isolated syndrome (RIS), or "asymptomatic MS", is detected on an MRI done for unrelated reasons, such as headache, head injury or screening in the airline industry. Even in these earliest stages there is evidence of end-organ damage. MRI in young people with CIS shows brain volume loss compared to controls [51] .
School performance in children who later develop MS, is poorer than their peers [52] , and a quarter of patients with RIS have significant cognitive impairment with a profile similar to patients with established MS [53] . This appears to indicate that not only is inflammation present prior to diagnosis, but there is accompanying neurodegeneration from the start.
We predict that MS has the potential to become a model neurodegenerative disease, setting the stage for presymptomatic diagnosis for other neurodegenerative diseases, in particular Alzheimer's and Parkinson's disease. The big question is whether society is ready for population screening and presymptomatic diagnosis? At some point in time we are going to have accept that to have a meaningful impact on the burden associated with neurodegenerative disease we are going to have to diagnose these conditions in the presymptomatic phase. Table 1 lists the most common MS differential diagnoses or mimics. Red flags include a first relapse at an older age, where vascular disease is more likely. Non-specific white matter lesions may be seen in patients with no objective persisting neurological disability and history of migraine, although migraine is more common in the MS population [54] . In those from low prevalence areas and/or ethnic minorities, differential diagnoses must be carefully considered, as neurosarcoidosis, NMOSD and infections such as TB are more likely, and MSspecific disease modifying therapy may cause a worsening of these diseases.
Important differential diagnoses
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Another red flag is comorbid systemic symptoms and signs; this should alert clinicians to exclude multisystem diseases such as SLE, Sjogren's, Behcet's, Susac's and other vasculitides. MS can coexist with other autoimmune diseases, and so the presence of these does not necessarily exclude MS, and the overall clinical picture must be carefully considered.
We would advise a diagnostic lumbar puncture in all patients presenting with possible MS.
CSF analysis is helpful in both identifying MS mimics and either supporting or arguing against a diagnosis of MS. CNS synthesis of oligoclonal IgG bands or OCBs can now be used to establish dissemination in time; this will hopefully lead to a renaissance in the use of CSF for diagnostic, prognostic and treatment response purposes. 
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This article is protected by copyright. All rights reserved. The role of MRI in establishing prognosis and treatment response is wide ranging.
Traditionally, lesion accrual/count, together with "active" lesions (gadolinium-enhancing) has been used to estimate disease activity, however correlation with long term outcomes is imperfect. The importance of brain atrophy seen on volumetric MRI is increasingly realised, as when taken alongside lesion load there is good correlation with long-term clinical outcomes [57] . 
Treatment and management of MS
The treatment of MS can be divided up into disease modifying therapies that tend to be MSspecific, and symptomatic therapies that are often used in different disease areas to treat symptoms resulting from neurological dysfunction.
(i) Disease modifying therapies
As the number, and efficacy, of disease modifying therapies has increased, interest in early treatment of MS in order to prevent long-term disability has grown. Historically, treatments have been immunosuppressant (including fingolimod, natalizumab, ocrelizumab) or immunomodulatory (such as interferon-beta, glatiramer acetate, teriflunomide), meaning that ongoing treatment is required to maintain suppression of inflammation (and disease activity).
Immune reconstitution therapies (including alemtuzumab and cladribine), can be given as short courses with the aim of producing enduring immunological actions -this is as close as we have to a potential cure for MS. This raises the question to as to whether early, or even pre-symptomatic, treatment can prevent clinically apparent disease. Patients with co-morbid disease, in particular vascular disease and smoking, have a poorer outcome with more rapidly progressive disease [22] . Recurrent infections such as urinary tract infections, may not only result in transient worsening of MS-related symptoms but could upregulate mechanisms known to speed-up worsening disability.
Although the evidence supporting lifestyle and wellness modifications in MS is weak, the value of these for general health is important. Patients who exercise do better than those who don't. Patients should be encouraged to have four to five aerobic exercise sessions per week.
They should avoid vigorous exercise during relapse, as this may cause excessive energy demands on an already compromised pathway, and theoretically could increase neuroaxonal loss. In patients with significant disability, a bespoke exercise programme should be designed to allow them to exercise, which is best done in conjunction with a physiotherapist with experience in neurodisability.
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The fact that aetiological factors implicated in MS development have the potential to be modified prior to disease development opens the door to the potential for preventive trials.
However, these would need to be enriched for a high-risk population group, and will take many years to set up. In the meantime, early treatment of those at risk of long term disability is needed in order to minimise the physical morbidity associated with MS. Table 2 Diagnostic criteria for relapsing remitting and primary progressive multiple sclerosis 
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